KR101288729B1 - 약물 전달용 중합체성 마이셀 - Google Patents

약물 전달용 중합체성 마이셀 Download PDF

Info

Publication number
KR101288729B1
KR101288729B1 KR1020077024561A KR20077024561A KR101288729B1 KR 101288729 B1 KR101288729 B1 KR 101288729B1 KR 1020077024561 A KR1020077024561 A KR 1020077024561A KR 20077024561 A KR20077024561 A KR 20077024561A KR 101288729 B1 KR101288729 B1 KR 101288729B1
Authority
KR
South Korea
Prior art keywords
side chain
amino acid
nitrogen
group
saturated
Prior art date
Application number
KR1020077024561A
Other languages
English (en)
Korean (ko)
Other versions
KR20080015070A (ko
Inventor
쿠르트 브레이튼캠프
케빈 실
하바이브 스카프
레베카 브레인튼캠프
Original Assignee
인터자인 테크놀로지스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인터자인 테크놀로지스, 인코포레이티드 filed Critical 인터자인 테크놀로지스, 인코포레이티드
Publication of KR20080015070A publication Critical patent/KR20080015070A/ko
Application granted granted Critical
Publication of KR101288729B1 publication Critical patent/KR101288729B1/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/40—Polyamides containing oxygen in the form of ether groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C08G73/028—Polyamidoamines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
KR1020077024561A 2005-04-01 2006-04-03 약물 전달용 중합체성 마이셀 KR101288729B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US66726005P 2005-04-01 2005-04-01
US60/667,260 2005-04-01
US74178005P 2005-12-01 2005-12-01
US60/741,780 2005-12-01
PCT/US2006/012382 WO2006107903A2 (en) 2005-04-01 2006-04-03 Polymeric micelles for drug delivery

Publications (2)

Publication Number Publication Date
KR20080015070A KR20080015070A (ko) 2008-02-18
KR101288729B1 true KR101288729B1 (ko) 2013-07-23

Family

ID=36951510

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077024561A KR101288729B1 (ko) 2005-04-01 2006-04-03 약물 전달용 중합체성 마이셀

Country Status (13)

Country Link
US (6) US7638558B2 (US07638558-20091229-C00440.png)
EP (1) EP1907444B1 (US07638558-20091229-C00440.png)
JP (1) JP4390845B2 (US07638558-20091229-C00440.png)
KR (1) KR101288729B1 (US07638558-20091229-C00440.png)
AT (1) ATE440117T1 (US07638558-20091229-C00440.png)
AU (1) AU2006231452B2 (US07638558-20091229-C00440.png)
CA (1) CA2603853C (US07638558-20091229-C00440.png)
DE (1) DE602006008625D1 (US07638558-20091229-C00440.png)
ES (1) ES2332062T3 (US07638558-20091229-C00440.png)
IL (1) IL186254A (US07638558-20091229-C00440.png)
MX (1) MX2007012157A (US07638558-20091229-C00440.png)
NZ (1) NZ562064A (US07638558-20091229-C00440.png)
WO (1) WO2006107903A2 (US07638558-20091229-C00440.png)

Families Citing this family (195)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080281041A1 (en) 1999-06-07 2008-11-13 Rozema David B Reversibly Masked Polymers
US8138383B2 (en) * 2002-03-11 2012-03-20 Arrowhead Madison Inc. Membrane active heteropolymers
US8008355B2 (en) * 2002-03-11 2011-08-30 Roche Madison Inc. Endosomolytic poly(vinyl ether) polymers
AU2003230761A1 (en) * 2002-03-29 2003-10-13 Abbott Laboratories Polymeric micelle formulations of hydrophobic compounds and methods
US9198887B2 (en) 2003-09-15 2015-12-01 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use
EP1670449B1 (en) 2003-09-15 2012-06-27 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use in angiogenesis
US8668926B1 (en) 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
US20050214379A1 (en) * 2004-01-02 2005-09-29 Sandro Mecozzi Encapsulation of chemical compounds in fluorous-core and fluorous-inner-shell micelles formed from semifluorinated-block or fluorinated-block copolymers
WO2006074202A2 (en) * 2005-01-04 2006-07-13 Intezyne Technologies, Incorporated Synthesis of hybrid block copolymers and uses thereof
US9498536B2 (en) 2005-09-15 2016-11-22 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders
US10130686B2 (en) 2005-09-15 2018-11-20 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders
US20100209382A1 (en) 2005-09-16 2010-08-19 Ordway Research Institute, Inc. Polyphenol Conjugates as RGD-Binding Compounds and Methods of Use
EP2010475A2 (en) 2006-04-27 2009-01-07 Intezyne Technologies Incorporated Heterofunctional poly(ethylene glycol) containing acid-labile amino protecting groups and uses thereof
US7560588B2 (en) 2006-04-27 2009-07-14 Intezyne Technologies, Inc. Poly(ethylene glycol) containing chemically disparate endgroups
US20080035667A1 (en) * 2006-06-07 2008-02-14 Osg Norwich Pharmaceuticals, Inc. Liquid delivery system
US20100015068A1 (en) * 2006-07-06 2010-01-21 Massachusetts Institute Of Technology Methods and Compositions For Altering Biological Surfaces
US8066824B2 (en) * 2006-07-07 2011-11-29 Intezyne Technologies, Inc. Covalent modification of metal surfaces
CA2660842C (en) * 2006-08-18 2012-03-13 F. Hoffmann-La Roche Ag Polyconjugates for in vivo delivery of polynucleotides
WO2008070284A2 (en) 2006-10-16 2008-06-12 Johnnie B. Byrd, Sr. Alzheimer's Center And Research Institute Amyloid beta peptides and methods of uses thereof
US8414927B2 (en) * 2006-11-03 2013-04-09 Boston Scientific Scimed, Inc. Cross-linked polymer particles
JP5569899B2 (ja) * 2006-11-28 2014-08-13 ウィスコンシン・アラムナイ・リサーチ・ファウンデーション 揮発性のフッ化麻酔薬を静脈内送達するためのフルオロポリマーベースのエマルション
EP2101734B1 (en) * 2006-12-01 2013-01-23 The Regents of the University of California Vesicles of self-assembling block copolymers and methods for making and using the same
WO2008070141A2 (en) * 2006-12-06 2008-06-12 Wisconsin Alumni Research Foundation Compositions for delivery of therapeutic agents
JP2010513526A (ja) * 2006-12-22 2010-04-30 シーエルエフ メディカル テクノロジー アクセラレーション プログラム インコーポレイテッド 甲状腺ホルモン類縁体、拮抗剤および製剤のためのナノ粒子及び重合体製剤ならびにその使用
CA2673622A1 (en) * 2006-12-22 2008-07-03 Imuthes Limited Lipid
US8900562B2 (en) * 2007-01-12 2014-12-02 Wisconsin Alumni Research Foundation Semi-fluorinated block copolymers for delivery of therapeutic agents
WO2008089485A2 (en) * 2007-01-19 2008-07-24 The Cleveland Clinic Foundation Carboxyethylpyrrole compounds and methods of their production
WO2008089487A2 (en) * 2007-01-19 2008-07-24 The Cleveland Clinic Foundation Carboxyethylpyrrole compounds and methods of their production
US7758635B2 (en) * 2007-02-13 2010-07-20 Boston Scientific Scimed, Inc. Medical device including cylindrical micelles
EP2131814A4 (en) * 2007-02-26 2011-08-03 Wisconsin Alumni Res Found POLYMIC MICROMS FOR THE RELEASE OF ACTIVE COMPOUNDS
US7618944B2 (en) * 2007-03-01 2009-11-17 Intezyne Technologies, Inc. Encapsulated amyloid-beta peptides
WO2008134734A2 (en) * 2007-04-30 2008-11-06 Intezyne Technologies, Inc. Encapsulated contrast agents
CA2685350C (en) * 2007-04-30 2013-10-15 Intezyne Technologies, Inc. Hybrid block copolymer micelles with mixed stereochemistry for encapsulation of hydrophobic agents
US9084771B2 (en) 2007-05-17 2015-07-21 Sutter West Bay Hospitals Methods and compositions for treating cancer
WO2009061473A2 (en) * 2007-11-07 2009-05-14 Mallinckrodt Inc. Photonic shell-core cross linked and functionalized nanostructures for biological applications
WO2009073193A2 (en) * 2007-12-03 2009-06-11 The Johns Hopkins University Methods of synthesis and use of chemospheres
ES2648196T3 (es) 2008-02-07 2017-12-29 The University Of Washington Dispositivo aerosol circunferencial
US20090232762A1 (en) * 2008-03-11 2009-09-17 May Pang Xiong Compositions for delivery of therapeutic agents
US8034396B2 (en) 2008-04-01 2011-10-11 Tyco Healthcare Group Lp Bioadhesive composition formed using click chemistry
JP5317031B2 (ja) * 2008-05-07 2013-10-16 公立大学法人大阪府立大学 ヘッド−テイル型共重合体の中空ナノ微粒子
GB2475183B (en) * 2008-06-04 2011-11-23 Gw Pharma Ltd Cannabinoids in combination with non-cannabinoid chemotherapeutic agent that are selective estrogen receptor modulators
GB2471987B (en) 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
CN101808668B (zh) * 2008-07-29 2012-06-27 那野伽利阿株式会社 药物内包活性靶向型高分子微团、医药组合物
JP5529874B2 (ja) * 2008-09-25 2014-06-25 インヴィーヴォ セラプーティクス コーポレーション 脊髄の損傷、炎症および免疫疾患に用いられる局所的に放出を制御しうる治療薬
US20110250297A1 (en) * 2008-09-25 2011-10-13 Oronsky Bryan T Treatment of Hyperproliferative Disorders Using Cardiac Glycosides
WO2010042823A1 (en) * 2008-10-09 2010-04-15 Northeastern Universtiy Multifunctional self-assembling polymeric nanosystems
US9464300B2 (en) 2008-11-06 2016-10-11 University Of Washington Multiblock copolymers
AU2013204152B2 (en) * 2008-11-06 2016-04-14 Phaserx, Inc. Multiblock copolymers
US20100159021A1 (en) * 2008-12-23 2010-06-24 Paul Davis Small Molecule Ligands of the Integrin RGD Recognition Site and Methods of Use
US8969473B2 (en) 2009-02-21 2015-03-03 Sofradim Production Compounds and medical devices activated with solvophobic linkers
WO2010095055A1 (en) 2009-02-21 2010-08-26 Sofradim Production Crosslinked fibers and method of making same using uv radiation
US8968733B2 (en) 2009-02-21 2015-03-03 Sofradim Production Functionalized surgical adhesives
CA2753188A1 (en) 2009-02-21 2010-08-26 Tyco Healthcare Group Lp Medical devices having activated surfaces
CA2753173C (en) 2009-02-21 2017-05-30 Sofradim Production Medical devices with an activated coating
US8512728B2 (en) 2009-02-21 2013-08-20 Sofradim Production Method of forming a medical device on biological tissue
AU2010215192B2 (en) 2009-02-21 2015-04-30 Sofradim Production Amphiphilic compounds and self-assembling compositions made therefrom
AU2010215200A1 (en) 2009-02-21 2011-10-13 Sofradim Production Apparatus and method of reaching polymers by exposure to UV radiation to produce injectable medical devices
US9039979B2 (en) 2009-02-21 2015-05-26 Sofradim Production Apparatus and method of reacting polymers passing through metal ion chelated resin matrix to produce injectable medical devices
US8535477B2 (en) 2009-02-21 2013-09-17 Sofradim Production Medical devices incorporating functional adhesives
US8877170B2 (en) 2009-02-21 2014-11-04 Sofradim Production Medical device with inflammatory response-reducing coating
US8663689B2 (en) 2009-02-21 2014-03-04 Sofradim Production Functionalized adhesive medical gel
EP2398941B1 (en) 2009-02-21 2016-07-13 Sofradim Production Crosslinked fibers and method of making same by extrusion
AU2010215936B2 (en) 2009-02-21 2015-03-05 Covidien Lp Medical devices having activated surfaces
US9180107B2 (en) * 2009-03-31 2015-11-10 Nanopharmaceuticals Llc Combination treatment of cancer with cetuximab and tetrac
US8524784B2 (en) * 2009-04-30 2013-09-03 Intezyne Technologies, Incorporated Polymer micelles containing anthracylines for the treatment of cancer
WO2010127271A1 (en) * 2009-04-30 2010-11-04 Intezyne Technologies, Incorporated Polymer micelles containing anthracylines for the treatment of cancer
US8287910B2 (en) * 2009-04-30 2012-10-16 Intezyne Technologies, Inc. Polymeric micelles for polynucleotide encapsulation
US20100292432A1 (en) * 2009-04-30 2010-11-18 Intezyne Technologies, Incorporated Polymers for polynucleotide encapsulation
KR20120094546A (ko) * 2009-05-04 2012-08-24 인터자인 테크놀로지스, 인코포레이티드 종양 치료를 위한 ｓｎ―３８을 함유하는 폴리머 미셀
EP2442800B1 (en) 2009-06-17 2019-04-24 NanoPharmaceuticals LLC Nanoparticle and polymer formulations for thyroid hormone, analogs, antagonists, and formulations and uses thereof
WO2011038278A2 (en) 2009-09-25 2011-03-31 Wisconsin Alumni Research Foundation Micelle encapsulation of therapeutic agents
US9415113B2 (en) 2009-11-18 2016-08-16 University Of Washington Targeting monomers and polymers having targeting blocks
WO2011102904A1 (en) * 2010-02-19 2011-08-25 Robert Shorr Imageable lipid-oil-water nanoemulsion therapeutic delivery system
WO2011102906A1 (en) * 2010-02-19 2011-08-25 Robert Shorr Imageable lipid-oil-water nanoemulsion delivery system
WO2011102905A1 (en) * 2010-02-19 2011-08-25 Robert Shorr Imageable lipid-oil-water nanoemulsion diagnostic delivery system
AP3284A (en) * 2010-02-24 2015-05-31 Arrowhead Res Corp Compositions for targeted delivery of SIRNA
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
WO2011113065A2 (en) * 2010-03-12 2011-09-15 Intezyne Technologies, Incorporated Pegylated polyplexes for polynucleotide delivery
AU2011231246B2 (en) 2010-03-25 2015-05-21 Sofradim Production Surgical fasteners and methods for sealing wounds
WO2011117744A2 (en) 2010-03-25 2011-09-29 Sofradim Production Medical devices incorporating functional adhesives
FR2958649B1 (fr) * 2010-04-07 2012-05-04 Arkema France Copolymere a blocs issu de matieres renouvelables et procede de fabrication d'un tel copolymere a blocs
WO2011143524A2 (en) * 2010-05-14 2011-11-17 Mallinckrodt Llc Functional, cross-linked nanostructures for tandem optical imaging and therapy
WO2012006147A1 (en) 2010-06-29 2012-01-12 Tyco Healthcare Group Lp Microwave-powered reactor and method for in situ forming implants
CA2804251A1 (en) 2010-07-01 2012-01-05 Sofradim Production Medical device with predefined activated cellular integration
WO2012018594A2 (en) * 2010-07-26 2012-02-09 Scott & White Healthcare Plant-derived polysaccharides for delivery of rna-based therapies
CA2805987C (en) 2010-07-27 2019-04-09 Sofradim Production Polymeric fibers having tissue reactive members
SG188281A1 (en) 2010-08-23 2013-04-30 Univ California Compositions and uses of materials with high antimicrobial activity and low toxicity
US10758578B2 (en) 2010-12-01 2020-09-01 Gowey Research Group PLLC Herbal formulations of carnivorous plants and methods for treating inflammation
US11344505B1 (en) 2010-12-01 2022-05-31 Gowey Research Group, Pllc Herbal formulations of carnivorous plants and methods for treating inflammation
US10744151B1 (en) * 2010-12-01 2020-08-18 Gowey Research Group PLLC Micro-RNA profiling, compositions, and methods of treating diseases
US11414663B2 (en) 2010-12-01 2022-08-16 Gowey Research Group, Pllc Micro-RNA profiling, compositions, and methods of treating diseases
US8802240B2 (en) 2011-01-06 2014-08-12 Nanopharmaceuticals Llc Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells
EP4088769A1 (en) 2011-03-03 2022-11-16 Impel Pharmaceuticals Inc. Nasal drug delivery device
WO2012138730A1 (en) * 2011-04-04 2012-10-11 Board Of Regents Of The University Of Nebraska Drug delivery compositions and methods
JP5992504B2 (ja) 2011-04-11 2016-09-14 カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチＣｏｕｎｃｉｌ Ｏｆ Ｓｃｉｅｎｔｉｆｉｃ ＆ Ｉｎｄｕｓｔｒｉａｌ Ｒｅｓｅａｒｃｈ ナノコンテナの表面誘発分解
EP3851142A1 (en) 2011-05-09 2021-07-21 Impel NeuroPharma Inc. Nozzles for nasal drug delivery
WO2012162307A2 (en) * 2011-05-23 2012-11-29 University Of Massachusetts Crosslinked polymer nano-assemblies and uses thereof
EP2543671A1 (de) * 2011-07-08 2013-01-09 cynora GmbH Querverknüpfung und Stabilisierung von organischen Metallkomplexen in Netzwerken
US8808734B2 (en) * 2011-07-11 2014-08-19 Full Spectrum Laboratories Limited Cannabinoid formulations
US9901616B2 (en) 2011-08-31 2018-02-27 University Of Georgia Research Foundation, Inc. Apoptosis-targeting nanoparticles
US8609146B2 (en) 2011-09-19 2013-12-17 Intezyne Technologies, Inc. Multi-block copolymers for the preparation of stabilized micelles
KR101334420B1 (ko) * 2011-11-17 2013-11-29 재단법인대구경북과학기술원 약물 전달을 위한 코어 크로스링킹된 고분자 마이셀 화합물 및 이의 제조방법
TWI568453B (zh) * 2011-11-22 2017-02-01 原創生醫股份有限公司 具有螯合型複合微胞之藥物載體及其應用
WO2013090648A1 (en) 2011-12-16 2013-06-20 modeRNA Therapeutics Modified nucleoside, nucleotide, and nucleic acid compositions
WO2013123298A1 (en) 2012-02-17 2013-08-22 University Of Georgia Research Foundation, Inc. Nanoparticles for mitochondrial trafficking of agents
WO2013124867A1 (en) 2012-02-21 2013-08-29 Amrita Vishwa Vidyapeetham University Polymer - polymer or polymer - protein core - shell nano medicine loaded with multiple drug molecules
EP2634193B1 (en) * 2012-02-29 2015-01-14 Enzypep B.V. Side-chain protected oligopeptide fragment condensation using subtilisins in organic solvents
JP2015518705A (ja) 2012-04-02 2015-07-06 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ヒト疾患に関連する生物製剤およびタンパク質の産生のための修飾ポリヌクレオチド
JP2015516143A (ja) 2012-04-02 2015-06-08 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ヒト疾患に関連するタンパク質の産生のための修飾ポリヌクレオチド
US20140113879A1 (en) * 2012-04-11 2014-04-24 Intezyne Technologies, Inc. Block copolymers for stable micelles
US9944752B2 (en) 2012-04-11 2018-04-17 Intezyne Technologies, Inc. Block copolymers for stable micelles
JP5927338B2 (ja) * 2012-04-11 2016-06-01 インテザイン テクノロジーズ， インコーポレイテッド 安定なミセルのためのブロックコポリマー
US20140127271A1 (en) * 2012-04-11 2014-05-08 Intezyne Technologies, Inc. Block copolymers for stable micelles
JP6251689B2 (ja) * 2012-08-28 2017-12-20 オリジナル バイオメディカルズ カンパニー，リミテット キレート化複合ミセルを含有する医薬組成物の放出制御方法
US20140134601A1 (en) * 2012-11-09 2014-05-15 Korea University Research And Business Foundation Use of protein nanoparticle based hydrogel
KR101403191B1 (ko) * 2012-11-19 2014-06-02 가톨릭대학교 산학협력단 약물 전달을 위한 야누스 및 다중 결합 미셀 및 이의 제조 방법
WO2014141289A1 (en) 2013-03-12 2014-09-18 Amrita Vishwa Vidyapeetham University Photo - chemo composition on the basis of microcapsules with a core -shell structure
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
WO2014152211A1 (en) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US9784730B2 (en) 2013-03-21 2017-10-10 University Of Washington Through Its Center For Commercialization Nanoparticle for targeting brain tumors and delivery of O6-benzylguanine
EP2983674A4 (en) 2013-04-08 2017-05-10 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
WO2014179228A1 (en) 2013-04-28 2014-11-06 Impel Neuropharma Inc. Medical unit dose container
US9775928B2 (en) 2013-06-18 2017-10-03 Covidien Lp Adhesive barbed filament
GB2516814B (en) 2013-06-19 2016-08-31 Otsuka Pharma Co Ltd Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015034928A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
FR3011550B1 (fr) * 2013-10-07 2016-11-18 Arkema France Copolymere a blocs polyamide et a bloc polyether
US20170080093A1 (en) * 2013-10-22 2017-03-23 Tyme, Inc. Tyrosine Derivatives And Compositions Comprising Them
US9585841B2 (en) * 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them
US10060934B2 (en) 2013-11-18 2018-08-28 Nanopharmaceuticals Llc Methods for screening patients for resistance to angioinhibition, treatment and prophylaxis thereof
EP3985118A1 (en) 2013-11-22 2022-04-20 MiNA Therapeutics Limited C/ebp alpha short activating rna compositions and methods of use
US9763992B2 (en) 2014-02-13 2017-09-19 Father Flanagan's Boys' Home Treatment of noise induced hearing loss
US10398663B2 (en) 2014-03-14 2019-09-03 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
US9622970B2 (en) * 2014-05-08 2017-04-18 Yaguang Liu Pharmaceutical composition containing lutein and antioxidant for treating and preventing human disease
WO2015179402A1 (en) 2014-05-19 2015-11-26 North Carolina State University Methods of folding a graft copolymer with dual anticancer drugs and related applications
CA2955250A1 (en) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2016014846A1 (en) 2014-07-23 2016-01-28 Moderna Therapeutics, Inc. Modified polynucleotides for the production of intrabodies
US11111284B2 (en) 2014-08-21 2021-09-07 The General Hospital Corporation Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing
WO2016054432A1 (en) 2014-10-01 2016-04-07 The Regents Of The University Of California Non-ionic and thermoresponsive diblock copolypeptide hydrogels for delivery of molecules and cells
CN104448300B (zh) * 2014-12-09 2017-01-11 西安医学院 低分子量l-聚谷氨酸-丝裂霉素c及其合成方法和应用
US11633355B2 (en) 2014-12-12 2023-04-25 Clemson University Research Foundation Multi-functional particles and methods of using the same
US10232050B1 (en) 2014-12-12 2019-03-19 Clemson University Multi-functional particles and methods of using the same
US9956300B2 (en) * 2015-03-18 2018-05-01 Duke Univerity Hydrogels formed from polypeptide micelles and methods of use thereof
FR3034423B1 (fr) * 2015-04-03 2019-05-31 Cnrs Dispersion aqueuse de particules d'au moins un polymere thermoplastique, son procede de preparation et ses applications, notamment pour l'ensimage de fibres de renfort
CA2986423C (en) 2015-05-18 2022-05-10 The Arizona Board Of Regents On Behalf Of The University Of Arizona Enhanced melanoma cancer prevention by novel melanotropins
JP2018520113A (ja) * 2015-05-26 2018-07-26 インテザイン テクノロジーズ， インコーポレイテッド 磁性造影剤としての鉄安定化ミセル
IL257845B (en) 2015-09-10 2022-07-01 Impel Neuropharma Inc Lined nasal delivery device
MA46023A (fr) 2015-10-22 2019-07-03 Modernatx Inc Vaccin contre le virus de la grippe à large spectre
KR20180096592A (ko) 2015-10-22 2018-08-29 모더나티엑스, 인크. 호흡기 세포융합 바이러스 백신
RS63381B1 (sr) 2015-10-22 2022-08-31 Modernatx Inc Vakcine protiv respiratornih virusa
CA3002922A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
US20180303929A1 (en) 2015-10-22 2018-10-25 Moderna TX, Inc. Herpes simplex virus vaccine
SG11201803360UA (en) 2015-10-22 2018-05-30 Modernatx Inc Nucleic acid vaccines for varicella zoster virus (vzv)
RS63135B1 (sr) 2015-12-23 2022-05-31 Modernatx Inc Postupci upotrebe polinukleotida koji kodiraju ox40 ligand
EP3400023A1 (en) 2016-01-10 2018-11-14 ModernaTX, Inc. Therapeutic mrnas encoding anti ctla-4 antibodies
KR101905010B1 (ko) 2016-04-19 2018-10-08 앱티스 주식회사 코엔자임 q10 가용화 조성물 및 이의 제조방법
AU2017279536A1 (en) 2016-06-07 2018-12-20 Nanopharmaceuticals, Llc Non-cleavable polymer conjugated with αvβ3 integrin thyroid antagonists
US10548908B2 (en) 2016-09-15 2020-02-04 Nostopharma, LLC Compositions and methods for preventing and treating heterotopic ossification and pathologic calcification
WO2018148432A1 (en) 2017-02-08 2018-08-16 Intezyne Technologies, Inc. Sn-38 loaded iron crosslinked micelle and methods thereof
CN110591078B (zh) * 2017-06-26 2021-11-05 苏州大学 还原/pH双重响应性阿霉素前药的制备方法
CA3075219A1 (en) 2017-09-08 2019-03-14 Mina Therapeutics Limited Hnf4a sarna compositions and methods of use
WO2019048645A1 (en) 2017-09-08 2019-03-14 Mina Therapeutics Limited STABILIZED COMPOSITIONS OF SMALL ACTIVATOR RNA (PARNA) FROM CEBPA AND METHODS OF USE
WO2019094702A1 (en) 2017-11-10 2019-05-16 Cocoon Biotech Inc. Ocular applications of silk-based products
WO2019104192A1 (en) 2017-11-21 2019-05-31 Impel Neuropharma, Inc. Intranasal device with inlet interface
US11571532B2 (en) 2017-11-21 2023-02-07 Impel Pharmaceuticals Inc. Intranasal device with dip tube
US11607384B2 (en) * 2017-12-08 2023-03-21 Western University Of Health Sciences Lipid emulsified drug delivery systems for chemoprevention and treatment
WO2019129657A1 (en) 2017-12-28 2019-07-04 Fundació Hospital Universitari Vall D'hebron - Institut De Recerca Actively targeted polymeric micelles for drug and gene delivery
EP3735223A4 (en) 2018-01-05 2021-10-13 Impel Neuropharma Inc. INTRANASAL ADMINISTRATION OF OLANZAPINE BY A PRECISION OLFACTORY DEVICE
ES2937440T3 (es) 2018-01-05 2023-03-28 Impel Pharmaceuticals Inc Administración intranasal de dihidroergotamina mediante un dispositivo olfativo de precisión
US10328043B1 (en) 2018-04-11 2019-06-25 Nanopharmaceuticals, Llc. Composition and method for dual targeting in treatment of neuroendocrine tumors
US11351137B2 (en) 2018-04-11 2022-06-07 Nanopharmaceuticals Llc Composition and method for dual targeting in treatment of neuroendocrine tumors
EP4242307A3 (en) 2018-04-12 2023-12-27 MiNA Therapeutics Limited Sirt1-sarna compositions and methods of use
CN109111582A (zh) * 2018-06-14 2019-01-01 哈尔滨工业大学无锡新材料研究院 一种聚醚胺-戊二酸共聚物胶团及其制备方法
KR20210034047A (ko) 2018-07-19 2021-03-29 임펠 뉴로파마 인코포레이티드 파킨슨 병 치료를 위한 레보도파 및 도파 데카르복실라아제 저해제의 기도 전달
WO2020033791A1 (en) 2018-08-09 2020-02-13 Verseau Therapeutics, Inc. Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
CA3125430A1 (en) 2019-01-03 2020-07-09 Impel Neuropharma, Inc. Nasal drug delivery device
US20220211740A1 (en) 2019-04-12 2022-07-07 Mina Therapeutics Limited Sirt1-sarna compositions and methods of use
KR20220010011A (ko) 2019-05-17 2022-01-25 임펠 뉴로파마 인코포레이티드 일회용 비강 전달 장치
CN112999151B (zh) * 2019-12-19 2024-03-19 鲁南制药集团股份有限公司 一种口服用紫杉醇复合胶束
KR102376945B1 (ko) * 2019-12-19 2022-03-21 상지대학교산학협력단 파킨슨병용 약제학적 조성물 및 그 치료제
CN113024789B (zh) * 2019-12-23 2023-01-06 福建省紫杉园药业有限责任公司 一种交联聚合物胶束及其制备方法和应用
CN111228301A (zh) * 2020-01-14 2020-06-05 哈尔滨医科大学 一种用于治疗血管生成介导疾病的复方制剂及其制备方法和应用
CN111297876B (zh) * 2020-01-16 2021-04-27 武汉理工大学 一种塞来昔布胶束和和厚朴酚胶束药物联用控释系统及其制备方法
US10961204B1 (en) 2020-04-29 2021-03-30 Nanopharmaceuticals Llc Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors
GB2603454A (en) 2020-12-09 2022-08-10 Ucl Business Ltd Novel therapeutics for the treatment of neurodegenerative disorders
JP2024501974A (ja) * 2020-12-28 2024-01-17 公益財団法人川崎市産業振興財団 ポリイオンコンプレックスミセル
TW202305133A (zh) 2021-03-26 2023-02-01 英商米納治療有限公司 Tmem173 sarna組合物及其使用方法
WO2023099884A1 (en) 2021-12-01 2023-06-08 Mina Therapeutics Limited Pax6 sarna compositions and methods of use
US11723888B2 (en) 2021-12-09 2023-08-15 Nanopharmaceuticals Llc Polymer conjugated thyrointegrin antagonists
GB202117758D0 (en) 2021-12-09 2022-01-26 Ucl Business Ltd Therapeutics for the treatment of neurodegenerative disorders
WO2023161350A1 (en) 2022-02-24 2023-08-31 Io Biotech Aps Nucleotide delivery of cancer therapy
WO2023170435A1 (en) 2022-03-07 2023-09-14 Mina Therapeutics Limited Il10 sarna compositions and methods of use
CN114957733B (zh) * 2022-05-12 2024-04-05 安徽工程大学 Boc-苯丙氨酸改性淀粉纳米粒子及其制备方法和在疏水药物负载的应用
CN114920869B (zh) * 2022-05-24 2023-07-14 太原工业学院 两亲性精氨酸嵌段环丙沙星共聚物、纳米颗粒及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1230934A1 (en) * 1999-11-19 2002-08-14 NanoCarrier Co., Ltd. Polyion complex micelles of core/shell structure

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2240547A (en) 1990-01-31 1991-08-07 Ciba Geigy Ag New compositions
KR940003548U (ko) * 1992-08-14 1994-02-21 김형술 세탁물 건조기
AU709345B2 (en) * 1995-09-07 1999-08-26 Emory University Therapeutic azide compounds
JPH11335267A (ja) 1998-05-27 1999-12-07 Nano Career Kk 水難溶性薬物を含有するポリマーミセル系
JP3523821B2 (ja) * 2000-02-09 2004-04-26 ナノキャリア株式会社 薬物が封入されたポリマーミセルの製造方法および該ポリマーミセル組成物
FR2814951B1 (fr) * 2000-10-06 2003-01-17 Flamel Tech Sa Suspension colloidale de particules submicroniques de vectorisation de principes actifs hydrophiles (insuline) et leur mode de preparation
FR2822834B1 (fr) * 2001-04-02 2005-02-25 Flamel Tech Sa Suspension colloidale de nanoparticules a base de copolymeres amphiphile pour la vectorisation de principes actifs et leur mode de preparation
US20040126900A1 (en) * 2001-04-13 2004-07-01 Barry Stephen E High affinity peptide- containing nanoparticles
US6881484B2 (en) * 2001-05-30 2005-04-19 Mitsubishi Kagaku Iatron, Inc. Core-shell particle including signal-generating substance enclosed therein and process for producing the same
US20050249786A1 (en) 2001-09-28 2005-11-10 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of amorphous compounds
US6780324B2 (en) * 2002-03-18 2004-08-24 Labopharm, Inc. Preparation of sterile stabilized nanodispersions
JP2004010479A (ja) * 2002-06-03 2004-01-15 Japan Science & Technology Corp ブロック共重合体とアンスラサイクリン系抗癌剤を含む新規固型製剤及びその製造法
JP2004018494A (ja) * 2002-06-19 2004-01-22 Japan Science & Technology Corp ブロック共重合体−薬剤複合体の製造法
JP4535229B2 (ja) 2003-05-08 2010-09-01 国立大学法人 東京大学 ポリエチレングリコール−ポリカチオンブロック共重合体
JP4763459B2 (ja) 2003-05-29 2011-08-31 株式会社東京大学Ｔｌｏ 安定化高分子ミセル
JP2006199590A (ja) * 2003-09-04 2006-08-03 Nano Career Kk 水溶性の塩基性薬物内包ナノ粒子含有組成物
US7311901B2 (en) * 2003-10-10 2007-12-25 Samyang Corporation Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery
EP1807436B1 (en) * 2004-10-25 2014-06-18 Intezyne Technologies Inc. Heterobifunctional poly(ethylene glycol) and uses thereof
IL165260A0 (en) 2004-11-16 2005-12-18 Yissum Res Dev Co Polymeric nano-shells
WO2006074202A2 (en) * 2005-01-04 2006-07-13 Intezyne Technologies, Incorporated Synthesis of hybrid block copolymers and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1230934A1 (en) * 1999-11-19 2002-08-14 NanoCarrier Co., Ltd. Polyion complex micelles of core/shell structure

Also Published As

Publication number Publication date
MX2007012157A (es) 2008-03-14
NZ562064A (en) 2011-03-31
CA2603853A1 (en) 2006-10-12
US8299128B2 (en) 2012-10-30
IL186254A0 (en) 2008-01-20
US8263663B2 (en) 2012-09-11
EP1907444A2 (en) 2008-04-09
JP4390845B2 (ja) 2009-12-24
EP1907444B1 (en) 2009-08-19
US20060240092A1 (en) 2006-10-26
US20130195987A1 (en) 2013-08-01
KR20080015070A (ko) 2008-02-18
AU2006231452B2 (en) 2011-05-26
AU2006231452A1 (en) 2006-10-12
US20110092668A1 (en) 2011-04-21
US8263665B2 (en) 2012-09-11
US20110091534A1 (en) 2011-04-21
WO2006107903A3 (en) 2007-02-15
IL186254A (en) 2012-04-30
DE602006008625D1 (de) 2009-10-01
US7638558B2 (en) 2009-12-29
ES2332062T3 (es) 2010-01-25
CA2603853C (en) 2013-11-19
WO2006107903A2 (en) 2006-10-12
US20100159020A1 (en) 2010-06-24
ATE440117T1 (de) 2009-09-15
US8426477B1 (en) 2013-04-23
JP2008537943A (ja) 2008-10-02
US8779008B2 (en) 2014-07-15

Similar Documents

Publication Publication Date Title
KR101288729B1 (ko) 약물 전달용 중합체성 마이셀
JP6740391B2 (ja) 安定なミセルのためのブロックコポリマー
JP2008537943A5 (US07638558-20091229-C00440.png)
JP5403826B2 (ja) 疎水性薬物のカプセル化のために混合立体化学を有するハイブリッドブロックコポリマー
US8747904B2 (en) Polymeric micelles for polynucleotide encapsulation
WO2011068916A1 (en) Pegylated polyplexes for polynucleotide delivery
JP2010526091A (ja) 癌の処置のための生物学的な標的基の改変
JP2010526091A5 (US07638558-20091229-C00440.png)
WO2011113065A2 (en) Pegylated polyplexes for polynucleotide delivery
US8524784B2 (en) Polymer micelles containing anthracylines for the treatment of cancer

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20160706

Year of fee payment: 4

FPAY Annual fee payment

Payment date: 20170710

Year of fee payment: 5

FPAY Annual fee payment

Payment date: 20180710

Year of fee payment: 6

FPAY Annual fee payment

Payment date: 20190709

Year of fee payment: 7